Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th:

Martin Midstream Partners L.P. (MMLP Quick QuoteMMLP - Free Report) : This company that engages in the terminalling, processing, storage, and packaging of petroleum products and by-products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.

Martin Midstream Partners L.P. Price and Consensus

Martin Midstream Partners L.P. price-consensus-chart | Martin Midstream Partners L.P. Quote

Martin Midstream Partners’ shares gained more than 100% over the last one month compared with the S&P 500 growth 14.7%. The company possesses a Momentum Score of A.

Martin Midstream Partners L.P. Price

Martin Midstream Partners L.P. price | Martin Midstream Partners L.P. Quote

Pixelworks, Inc. (PXLW Quick QuotePXLW - Free Report) : This company that develops and markets semiconductor and software solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.

Pixelworks, Inc. Price and Consensus

Pixelworks, Inc. price-consensus-chart | Pixelworks, Inc. Quote

Pixelworks’ shares gained 43.8% over the last one month. The company possesses a Momentum Score of A.

Pixelworks, Inc. Price

Pixelworks, Inc. price | Pixelworks, Inc. Quote

Can-Fite BioPharma Ltd. (CANF Quick QuoteCANF - Free Report) : This clinical-stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 19.9% over the last 60 days.

Can-Fite Biopharma Ltd Price and Consensus

Can-Fite Biopharma Ltd price-consensus-chart | Can-Fite Biopharma Ltd Quote

Can-Fite BioPharma’s shares gained 38.1% over the last one month. The company possesses a Momentum Score of A.

Can-Fite Biopharma Ltd Price

Can-Fite Biopharma Ltd price | Can-Fite Biopharma Ltd Quote

Abeona Therapeutics Inc. : This a clinical-stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 21.1% over the last 60 days.

Abeona Therapeutics Inc. Price and Consensus

Abeona Therapeutics Inc. price-consensus-chart | Abeona Therapeutics Inc. Quote

Abeona Therapeutics’ shares gained 22.8% over the last one month. The company possesses a Momentum Score of A.

Abeona Therapeutics Inc. Price

Abeona Therapeutics Inc. price | Abeona Therapeutics Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

The Hottest Tech Mega-Trend of All                

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>